slidedeck.co

Novo Nordisk A/S investor presentation, Q3 2026 investor presentation

Cover slide of the Novo Nordisk A/S 2026 investor presentation
Cover of Novo Nordisk A/S's 2026 investor presentation.

The deck opens with a title slide, an agenda and a forward-looking statements disclaimer, then moves into a Q3 2026 highlights page on the 2030 ambitions. Its main sections follow in order: commercial execution (sales growth by region and therapy area, the Wegovy pill and Ozempic pill rollouts, and US prescription share), research and development (CagriSema trial results, the pipeline timeline and upcoming milestones), and financials (adjusted operating profit, the raised 2026 outlook and key modelling assumptions). Later sections cover the updated corporate strategy, the 2030 ambitions, and detailed diabetes and obesity evidence. The deck ends with investor contacts and upcoming reporting dates, with an appendix of trial data by therapy area. Several slides are worth studying: the headline slide on 2030 ambitions condenses three goals into three columns with large numerals, the sales growth slide pairs two simple bar charts side by side, and the CagriSema pipeline slide uses a colour-coded timeline grid. The layouts are consistent throughout, with a repeated header, page number and footer source line on each page, though many slides carry dense text and footnotes.

Slides worth studying

  • Slide 4: Three columns with large numerals and short bullets make the headline results easy to scan in a single view.
  • Slide 5: Two paired bar charts with a highlighted callout show the growth trend and the net patient increase at a glance.
  • Slide 12: A colour-coded grid of milestones by therapy area and quarter gives a clear timeline of the pipeline.

Details

  • Company: Novo Nordisk A/S
  • Year: 2026
  • Type: Investor presentation
  • Industry: Pharmaceuticals
  • Pages: 98

The hosted copy of this deck is being prepared. Newsletter readers will find the download here.

Review score: 7 out of 10, Effective

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

The deck has a strong, consistent identity and mostly clear action titles with well-built charts and tables. Slides 4, 5 and 12 are legible and ordered, with large numerals, highlighted recent quarters and a colour-coded timeline grid. The weaknesses are consequential: the route is hard to follow because the agenda and the section order do not match (strategy and diabetes/obesity evidence arrive after financials), and the 72 pages inspected are dense with small type, long two-line titles and footnotes that only work as a read-ahead document. The forward-looking statements page (3) is unreadable small print, and the many trial-data slides (34 to 60) repeat one layout with little emphasis on what the audience should take away.

Worth keeping: Keep the action titles, the consistent header and brand colour system, and the clean bar charts on slide 5 with the shaded recent quarters.

Most useful repair: Align the agenda with the actual section order, add section dividers for strategy, and cut or split the dense evidence slides so each carries one dominant chart or number.

What would change the score: Raise the smallest text (footnotes, table cells on slides 12, 50 and 68) and move the trial-detail slides into a clearly labelled appendix.

Confidence medium. 72 of 98 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (98 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

Investor presentation / Q3 2026 / Lasting Health Starts Now / novo

Visuals: Full-bleed photograph of an older couple sitting side by side against a dark green-grey horizontal-plank wall in warm late-afternoon sunlight. The man on the left wears a dark flat cap, a white tank top and has a grey beard, looking up and to the right. The woman on the right wears rust-brown long-sleeve top, rimless-style glasses, short grey hair and a small earring, looking off to the right with a slight smile. In the foreground, out-of-focus green leaves blur across the lower centre. Left background shows a white picket fence, a small tree and a red roof, with a gravel ground. Lighting is warm directional sunlight from the right, casting shadows on the wall. Dominant colours are dark teal-green, rust brown, warm gold and white. The photo is uncropped at full bleed with a slight foreground blur overlay. White Novo logo (a stylised standing animal figure with a circle above and the wordmark 'novo' in lowercase rounded sans) with tagline 'Lasting Health Starts Now' sits over the photograph on the left.

Slide 2

2 / Investor presentation / Q3 2026

Agenda

Progress on 2030 ambitions

Commercial execution

Research & Development

Financials

Visuals: Novo logo (Novo Nordisk brand mark) in the bottom-right corner: a stylised bull/animal figure with a circular ring above its head, followed by the lowercase wordmark 'novo', rendered as a solid #00008F flat graphic. No photographs, charts or other illustrations.

Slide 3

3 / Investor presentation / Q3 2026 / novo / Forward-looking statements / Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo, / may contain certain forward-looking statements relating to the operating, research & development, financial and sustainability performance and results of Novo and/or the industry in which it operates. / Forward-looking statements can be identified by the fact that they do not relate to historical or current facts and include guidance. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘transition plan’, / ‘prospect’, ‘aspiration’, ‘ambition’, ‘upcoming’, ‘become’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning, as they relate to Novo or our / management, are intended to identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: / • Statements of targets, future guidance, (transition) plans, objectives, ambitions, aspirations or goals for future operations, including those related to operating, financial and sustainability matters, Novo’s / products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto; / • Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; / • Statements regarding future economic performance, future actions and outcome of contingencies, such as legal proceedings; and / • Statements regarding the assumptions underlying or relating to such statements. / By their very nature, forward-looking statements involve risks, uncertainties and assumptions, both general and specific, and actual results may differ materially from those contemplated, expressed or implied / by any forward-looking statement. / Factors that may affect future results include, but are not limited to, global as well as local political, economic and environmental conditions, such as interest rate and currency exchange rate fluctuations or / climate change, delay or stoppage or failure of projects related to clinical trial conduct or research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result / of interruptions or delays affecting supply chains on which Novo relies, shortages of supplies, including energy supplies, product recalls, unexpected contract breaches or terminations, government-mandated or / market-driven price decreases for Novo’s products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches (Novo has experienced events of IT / security breaches in the past), Novo’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related / interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, and taxation changes, including changes in tariffs / and duties, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, strikes and other / labour market disputes, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, effects of domestic or international crises, / civil unrest, war or other conflict and factors related to the foregoing matters and other factors not specifically identified herein. / For an overview of certain risks that could adversely affect Novo’s results or the accuracy of its forward-looking statements , reference is made to ‘Risks management’ in the Annual Report 2025. / None of Novo or its officers or employees accept any responsibility for the future accuracy of its forward-looking statements. / Unless required by law, Novo has no duty and undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Slide 4

4

Investor presentation

Q3 2026

2030 ambitions | Q3 highlights

novo

Grow and diversify pipeline

7

FHDs initiated

by end of October

10

ongoing phase 3

programmes

Diabetes

• CagriSema phase 3 trial REIMAGINE 5 successfully completed

• Zenagamtide phase 3 trial AMBITION 7 initiated

Obesity

• CagriSema 1.0/1.0 mg delivered 21% weight loss in phase 3 trial REDEFINE 9

• Oral zenagamtide phase 3 trial AMAZE 9 initiated

• Oral amylin 355 phase 2 trial initiated

Blood & endocrine disorders

• Frehemgo® (denecimig) positive opinion in EU and denecimig BLA review extended in US

Drive sustainable growth

47.8 million

people on obesity & diabetes treatments

22%

obesity sales growth at CER

Adjusted sales growth of 4% at CER

• GLP-1 volume growth across geographies

Wegovy® pill now launched in 8 markets globally

Wegovy® 7.2 mg SDD now launched in 18 markets globally

Ozempic® 2.0 mg launched in >10 markets

Deliver attractive returns

32 bDKK

generated in adjusted operating profit

>28 bDKK

generated in free cash flow

Adjusted operating profit growth of 27% at CER

• Favourably impacted by restructuring costs in Q3’25

Outlook raised for 2026¹

• Adj. sales growth of -2% to +2% at CER

• Adj. operating profit growth of -2% to +2% at CER

1 Outlook is presented as adjusted sales growth and adjusted operating profit growth to exclude certain exceptional and non-recurring effects, primarily of non-cash nature to enhance transparency and comparability of underlying operating performance.

BLA: Biologics license application; CER: Constant exchange rates; EU: European Union; FHD: First human dose; SDD: Single dose device; US: United States

Visuals: Three circular white icon badges (about 5.9% wide) sit centred on the top edge of the three navy card headers. Left badge: a pipeline icon in navy line art showing a row of three chevron arrows over a grid of small squares, some squares hatched diagonally and one bottom-right square with a small mark. Middle badge: a growth icon in navy line art showing a rising arrow above five ascending bar columns on a baseline. Right badge: an icon in navy line art of a hand holding a coin with a dollar sign and small sparkle dots. No photographs, charts or tables. Icons are navy line art on white, no shadows.

Slide 5

5 / Investor presentation / Q3 2026 / Growth recovery supported by more people treated across both / diabetes and obesity / CER group sales growth by quarter / Year-on-year change / People added on Novo diabetes and obesity treatments by quarter1 / Millions, sequential net change / Obesity / Diabetes / +2.5 million / net increase in people / on Novo treatments / 7% / 4% / -2% / -4% / 1.2 / 1.3 / 0.8 / 0.7 / 0.0 / -0.3 / 0.4 / 0.5 / 0.4 / 0.6 / -0.4 / -0.8 / Q4 2025 / Q1 2026 / Q2 2026 / Q3 2026 / Q4 2025 / Q1 2026 / Q2 2026 / Q3 2026 / 1Quarterly net additions. Based on the estimated total number of full-year people reached over a 12-month period reported in Novo’s quarterly financial reports / CER: Constant exchange rates

Visuals: Two vertical bar charts. Left chart: CER group sales growth by quarter, year-on-year change, in percent. Bars on a shared zero baseline (dark navy line across the full chart width). Values printed above or below each bar: Q4 2025 -2%, Q1 2026 -4%, Q2 2026 7%, Q3 2026 4%. Bars are all solid navy #00008F with no legend; the Q2 2026 and Q3 2026 columns sit on a light grey #F5F3F2 panel, and the labels Q2 2026 and Q3 2026 are bold. The bar heights are proportional: Q4 2025 bar about 2% below baseline, Q1 2026 about 4% below, Q2 2026 about 7% above, Q3 2026 about 4% above; no axis values printed. Right chart: People added on Novo diabetes and obesity treatments by quarter, millions, sequential net change. Stacked columns about the zero baseline with two series: Obesity (purple #8759E6, above baseline) and Diabetes (blue #0878CF, below and above baseline). Labelled values: Q4 2025 Obesity 0.4, Diabetes -0.4, net 0.0; Q1 2026 Obesity 0.5, Diabetes -0.8, net -0.3; Q2 2026 Obesity 0.8, Diabetes 0.4, net 1.2; Q3 2026 Obesity 0.7, Diabetes 0.6, net 1.3. Net totals sit above each stack in navy text, bold for Q2 and Q3 2026. Legend top-left of the chart: purple square labelled Obesity and blue square labelled Diabetes. The Q2 and Q3 2026 columns sit on a light grey #F5F3F2 panel, and a callout above them reads +2.5 million net increase in people on Novo treatments. No axis lines or gridlines; category labels Q4 2025, Q1 2026, Q2 2026, Q3 2026 sit under each chart. Novo logo: the Novo wordmark with a stylised bull-head emblem in navy #00008F at top-right.

Slide 6

6 / Investor presentation / Q3 2026 / novo / Adjusted Q3 sales growth of 4% driven by GLP-1 volume growth / Geographic adjusted sales split for Q3 2026 / Therapy area adjusted sales split for Q3 2026 / DKK billion / Insulin / GLP-1 diabetes / Other diabetes / Obesity / Blood & endocrine disorders / Growth at CER / 60 / 40 / 20 / 0 / 1% / 8% / International Operations / 18% / 6% / -7% / -5% / US / IO / EUCAN / Emerging / Markets / APAC / Region / China / DKK billion / US Operations / International Operations / Growth at CER / 100 / 80 / 60 / 40 / 20 / 0 / 4% / -7% / 2% / 22% / 15% / 8% / 1% / IO 24% / US 20% / IO 8% / US -13% / IO / -2% / -10% / US 27% / IO 6% / Total / GLP-1 / diabetes / Insulin / Obesity / Blood & / endocrine / disorders / 1 / ‘Other diabetes’ is included in Total / APAC: Japan, Korea, Oceania and Southeast Asia; CER: Constant exchange rates; Emerging Markets: mainly Latin America, Middle East and Africa; EUCAN: Europe and Canada; IO: International Operations; Region China: Mainland China, Hong Kong and Taiwan; / US: United States / 1

Visuals: Two stacked column charts. LEFT: 'Geographic adjusted sales split for Q3 2026', y-axis DKK billion from 0 to 60 with ticks at 0, 20, 40, 60; x categories US, IO, EUCAN, Emerging Markets, APAC, Region China. Series: Insulin (blue), GLP-1 diabetes (teal), Other diabetes (olive), Obesity (purple), Blood & endocrine disorders (orange-red). Values are not printed, so estimates are about: US total about 42 (insulin about 3, GLP-1 about 21, obesity about 15, blood about 3); IO total about 37 (insulin about 9, GLP-1 about 13, obesity about 11, blood about 3); EUCAN total about 20; Emerging Markets total about 8; APAC total about 5.5; Region China total about 5. Growth labels in navy outlined boxes above the bars: US 1%, IO 8%, EUCAN 18%, Emerging Markets 6%, APAC -7%, Region China -5%; the four international boxes sit inside a grey dashed rectangle labelled International Operations. Legend in two rows at top left: Insulin, GLP-1 diabetes, Other diabetes, Obesity, Blood & endocrine disorders, Growth at CER (outlined square). RIGHT: 'Therapy area adjusted sales split for Q3 2026', y-axis DKK billion from 0 to 100 with ticks every 20; categories Total (superscript 1), GLP-1 diabetes, Insulin, Obesity, Blood & endocrine disorders. Stacked series: US Operations (mid blue #3B97DE, bottom) and International Operations (light blue #B1D5F2, top). Estimates marked about: Total US about 41, IO about 37 (total about 78); GLP-1 diabetes US about 21, IO about 14 (total about 35); Insulin US about 2.5, IO about 9.5 (total about 12); Obesity US about 16, IO about 10 (total about 26); Blood & endocrine US about 2.5, IO about 2.5 (total about 5). Growth labels above each column: Total 4%, GLP-1 diabetes -7%, Insulin 2%, Obesity 22%, Blood & endocrine 15%. Segment labels: Total US 1%, Total IO 8%; GLP-1 IO -2%, US -10%; Insulin IO 8%, US -13%; Obesity IO 24%, US 20%; Blood & endocrine IO 6%, US 27%. Legend: US Operations, International Operations, Growth at CER (outlined square). Highlighted: the Total column and the grey International Operations box are the emphasis areas.

Slide 7

7

Investor presentation

Q3 2026

novo

International Operations performance driven by Wegovy®

IO GLP-1 sales for Q3 2026

IO GLP-1 performance supported by new launches

DKK

billion

GLP-1 diabetes

Obesity

Total GLP-1 growth at CER

30

25

20

15

10

5

0

8%

26%

-8%

-13%

-25%

Regions

IO

EUCAN

Emerging

Markets

APAC

Region China

Obesity portfolio is the key growth driver in IO

• IO GLP-1 sales increased by 8% in Q3, driven by obesity (+24%)

• Novo continues to be GLP-1 volume leader, with 54% market share

EUCAN is the key growth region in IO

• Strong performance across GLP-1 diabetes (+13%) and obesity (+47%)

driven by volume growth of Ozempic® and Wegovy®

• EUCAN performance negatively impacted by lower realised prices in

Canada following semaglutide loss of exclusivity

APAC: Japan, Korea, Oceania and Southeast Asia; CER: Constant exchange rates; Emerging Markets: mainly Latin America, Middle East and Africa; EUCAN: Europe and Canada; IO: International Operations; Region China: Mainland China, Hong Kong and Taiwan

Source: Volume market share based on information licensed from IQVIA, July 2026 volume data, R3M

Visuals: Stacked column chart. Title: 'IO GLP-1 sales for Q3 2026' (bold, centred over the chart at x 19.1, y 25.9). Y-axis: DKK billion, range 0 to 30, ticks every 5 (0, 5, 10, 15, 20, 25, 30), navy axis line. X-axis: five categories, IO, EUCAN, Emerging Markets, APAC, Region China, with a navy baseline. Series: GLP-1 diabetes (teal #0080A0, bottom segment) and Obesity (purple #8759E6, top segment). Legend across the top: teal square 'GLP-1 diabetes', purple square 'Obesity', hollow navy-outlined square 'Total GLP-1 growth at CER'. Values printed: none for the segments; the boxed labels are growth rates. IO: total bar about 24.3 (teal about 13.5, obesity about 10.8), labelled 8%. EUCAN: total about 15.5 (teal about 8.5, obesity about 7.0), labelled 26%. Emerging Markets: total about 4.0 (teal about 2.0, obesity about 2.0), labelled -8%. APAC: total about 3.1 (teal about 1.6, obesity about 1.5), labelled -13%. Region China: total about 1.8 (teal about 1.3, obesity about 0.5), labelled -25%. Growth labels sit in white boxes with a thin navy outline above each bar. A grey dashed rectangle with the label 'Regions' encloses EUCAN, Emerging Markets, APAC and Region China but not IO. Highlighted points: none.

Slide 8

8 / Investor presentation / Q3 2026 / novo / Novo is expanding its oral obesity leadership in International / Operations / Wegovy® pill rollout ahead of plan in IO / Today / Launched in 7 markets in IO / Q4 2026 / Further launches planned / H1 2027 / Available in >20 markets / Wegovy® pill leads oral obesity market / share in UK and UAE / Oral obesity market share (R4W) / Jul 2026 / Oct 2026 / ~90% / ~80% / Jun 2026 / Oct 2026 / Wegovy® pill / orforglipron / Initial insights from Germany / Early encouraging uptake mainly / driven by GLP-1 naïve patients / ~100k packs sold in six weeks since / launch / Key priority to build oral obesity market / • Uptake ahead of competitor, with / strong patient starts on Wegovy® pill / • Next lever: longer stay time, driven by: / 1 Patient support programmes / 2 Clear switch guidance / 3 Subscription offerings / R4W: rolling four weeks; IO: International Operations; sc: subcutaneous; UAE: United Arab Emirates; UK: United Kingdom; US: United States / Note: One pack is equivalent to one month of supply for patients. In IO, Wegovy® pill is launched in UAE, UK, Germany, Mexico, France, Poland, and Spain / Source: IQVIA weekly local in-market data, week 41 2026

Visuals: Three-part slide. (1) Left: vertical timeline of three purple circles (Today, Q4 2026, H1 2027) joined by a thin lavender-purple vertical line, each with a text label to its right. (2) Centre: a line-less stacked pair of 100% area charts titled 'Wegovy® pill leads oral obesity market share in UK and UAE'. Top chart: UK, x-axis Jul 2026 to Oct 2026, y-axis 'Oral obesity market share (R4W)' with no printed numeric scale; Wegovy® pill purple #8759E6 fills the upper area and orforglipron beige #DDD4C9 fills the lower area; beige rises from about Sep to a peak near Oct then falls; label ~90% in white at right. Bottom chart: UAE, x-axis Jun 2026 to Oct 2026; beige fills the lower area with purple above, purple share is high at start, dips around Jul to about the middle, rises to about 80% at Oct; label ~80% in white at right. Legend below centre chart: purple square Wegovy® pill, beige square orforglipron. Flag of United Kingdom in circle at top left of top chart; flag of United Arab Emirates in circle at top left of bottom chart; small Wegovy pill icons (white cow-like pictogram in circle) at right of each chart next to ~90% and ~80%. (3) Right: white box with thin purple border holding a German flag circle (black, red, gold horizontal bands) and two text lines; second white box with thin purple border holding a bullet list and three numbered purple-circle rows with lavender bars.

Slide 9

9 / Investor presentation / Q3 2026 / Wegovy® franchise captures more than 50% of new patient starts / in the US, with continued volume growth in Q3 / Wegovy® pill captures 8 out of 10 new / patients starting on oral obesity medicines / NBRx / market share / Wegovy® pill / orforglipron / 100% / 75% / 50% / 25% / ~80% / May / 2026 / Oct / 2026 / Total prescriptions / (million sold units) / Wegovy® pill / Wegovy® sc / 8 / 6 / 4 / 2 / ~3.6 / ~4.1 / Q1 2026 / Q2 2026 / Q3 2026 / Expanded patient options with Wegovy® pill & HD contribute to 2026 franchise volume growth / >8 million / cumulative prescriptions / since launch / ~20% / total volume growth in Q3 / versus Q2 / ~10% / total volume growth in Q3 / versus Q2 / >50% / NBRx share in the obesity / medication market / NBRx: New-to-brand prescriptions; sc: subcutaneous / Source: Weekly data for Wegovy pill is an estimate based on internal self-pay data and IQVIA Xponent, as of 2 October 2026. NBRx data for Wegovy® sc, tirzepatide and orforglipron is based on IQVIA Xponent, as of 2 October 2026

Visuals: Chart 1: 100% stacked area chart titled 'Wegovy® pill captures 8 out of 10 new patients starting on oral obesity medicines'. Y-axis 'NBRx market share' from 0% to 100% labelled at 25%, 50%, 75%, 100%; X-axis labelled May 2026 (left) to Oct 2026 (right), no tick values between. Two series: Wegovy® pill (purple #8759E6) on top, orforglipron (grey #A1A1A1) at the bottom; orforglipron rises from about 5% in May to about 20% in Oct, Wegovy® pill occupies the remainder, about 80% at the right edge (printed as '~80%'). Legend top-right of chart: purple swatch 'Wegovy® pill', grey swatch 'orforglipron'. Small white Novo cow icon sits on the purple area near the right edge above '~80%'. Chart 2: stacked bar chart titled 'Expanded patient options with Wegovy® pill & HD contribute to 2026 franchise volume growth' with y-axis 'Total prescriptions (million sold units)' ranging 0 to 8, gridline ticks at 2, 4, 6, 8. Three bars: Q1 2026 about 4.7 total (Wegovy® sc about 3.4 lilac, Wegovy® pill about 1.3 purple, estimated), Q2 2026 about 6.8 total (Wegovy® sc about 3.7, Wegovy® pill about 3.1, estimated), Q3 2026 total about 7.7 (Wegovy® sc printed ~4.1 lilac, Wegovy® pill printed ~3.6 purple). Legend top-right: purple 'Wegovy® pill', lilac 'Wegovy® sc'. No highlighted points. Panel: lavender box with three product rows, each with a logo and a KPI: Wegovy PILL logo with '>8 million cumulative prescriptions since launch'; Wegovy semaglutide injection logo with '~20%'? no: second row Wegovy semaglutide injection logo with '~10% total volume growth in Q3 versus Q2'; third row Wegovy logo with '>50% NBRx share in the obesity medication market'. Row 1 pairs the PILL logo with '>8 million', '~20% total volume growth in Q3 versus Q2'. Two thin light purple hairline dividers separate the rows.

Slide 10

10

Investor presentation

Q3 2026

novo

New patient starts now more than double compared to before

Ozempic® pill launch in the US

Ozempic® pill transition is complete, with all new patients

starting directly on the brand

Weekly NBRx (‘000s)

Rybelsus®

Ozempic® pill

Rybelsus® and Ozempic® pill

12

9

6

3

0

Jan

2025

Oct

2026

12

+100% NBRx

Launch of Ozempic® pill creates opportunity to expand

the oral GLP-1 type 2 diabetes market

• Ozempic®'s well-known brand improves patient awareness

• Commercial activities now for combined Ozempic® franchise

• Potential 25 mg Ozempic® pill approval in Q4 2026

>60% of Ozempic® pill NBRx are naïve to GLP-1s

NBRx: New-to-brand prescription; US: United States;

Note: Patients transitioning from Rybelsus® to Ozempic® pill are not counted as an NBRx

Source: IQVIA Xponent, as of 2 October 2026

Visuals: One line chart, titled by the bold left-column headline, with y-axis 'Weekly NBRx (‘000s)' ranging from 0 to 12 in steps of 3 (labels 0, 3, 6, 9, 12) and x-axis from Jan 2025 to Oct 2026 (labels Jan 2025 and Oct 2026 only). Three series: Rybelsus® as a solid navy #312B88 line starting near 3 in Jan 2025, rising to about 6.5 by mid 2025, then falling to about 0 by Oct 2026; Ozempic® pill as a solid red #E0262B line starting from 0 about mid 2025 and rising to about 12 by Oct 2026; Rybelsus® and Ozempic® pill as a dashed navy and red line that runs about 6 to 7 through early to mid 2025, then rises to about 12 by Oct 2026 with dips near 10.5 in late 2025 and 9.5 in early 2026; no printed values except the labels 12 at the right end and 12 at the start of the dashed reference line. A horizontal dashed blue line #1E73C8 is drawn at the 12 level from about x 26 to 47 percent, with a solid vertical blue arrow #0A7FD4 (about 1.2 percent wide, from y 50.5 to 63.3 percent) pointing up from the about 6.5 level, labelled '+100% NBRx' in navy. Legend at top right of chart: short navy solid line then Rybelsus®; short red solid line then Ozempic® pill; short navy dashed line then Rybelsus® and Ozempic® pill. Axes are thin navy lines: the vertical axis at about x 7 percent and horizontal baseline at y 80 percent. No highlighted points. Right panel: a pill icon inside a blue outline circle (about x 56 to 59 percent, y 52.9 to 58.2 percent) beside a callout. Logo graphics: Ozempic wordmark in red #E0262B; a twisted ribbon illustration of an orange #EE7803 ribbon and a navy #312B88 ribbon crossing each other, ending in an orange arrowhead pointing right; Rybelsus wordmark in navy with a purple to orange gradient; and a 'THERE'S ONLY ONE OZEMPIC [now]available in a pill' lockup in red and orange. No photographs.

Slide 11

11 / Investor presentation / Q3 2026 / novo / Strong R&D momentum across therapy areas while strengthening / CagriSema's launch profile / Q3 key R&D milestones achieved / Latest CagriSema data reinforces its efficacy across / doses and patient populations / Project / Q3 2026 / REIMAGINE 5 1 / CagriSema 1.0/1.0 mg / H2H vs. tirzepatide 5 mg / 12.4% / superior / weight loss / 1.71% / non-inferior HbA1c / reduction / Diabetes / CagriSema / ✓ Phase 3 results (REIMAGINE 5) / Zenagamtide (sc) / ✓ Phase 3 initiation (AMBITION) / Obesity / Amylin 355 (sc and oral) / ✓ Phase 2 initiation / CagriSema / ✓ Phase 3 results (REDEFINE 9) / Zenagamtide (sc) / ✓ Phase 3 initiation (CVOT) / Zenagamtide (oral) / ✓ Phase 3 initiation (AMAZE 9) / Blood & endocrine / Frehemgo®/ denecimig / ✓ EU positive opinion / Clinical milestones / Regulatory milestones / REDEFINE 9 1 / CagriSema 1.0/1.0 mg / 21% / weight loss / at 68 weeks / Post-hoc analysis 2 / (from REDEFINE 1) / CagriSema 2.4/2.4 mg / 25% / weight loss / for women / 27% / weight loss for pre- / menopausal women / Next steps for CagriSema in Obesity / • FDA regulatory decision expected in Q4 2026 / • Pending decision, full US launch expected during start of 2027 / • REDEFINE 11 and CagriSema HD planned readouts in H1’27 and H1’28 / 1 Results published in a Novo press release 21 September 2026. 2 Results available in a Novo press release 20 October 2026. / CVOT: Cardiovascular outcomes trial; EU: European Union; H2H: Head-to-head; HbA1c: Haemoglobin A1c; HD: High-dose; sc: subcutaneous; US: United States / Note: all clinical trial results presented on the slide are based on the efficacy estimand according to the trial protocol

Visuals: Table (left): 3 columns (row-group label, Project, Q3 2026) and 9 data rows. Row group Diabetes (blue #0878CF cell): CagriSema -> Phase 3 results (REIMAGINE 5); Zenagamtide (sc) -> Phase 3 initiation (AMBITION). Row group Obesity (purple #8759E6 cell): Amylin 355 (sc and oral) -> Phase 2 initiation; CagriSema -> Phase 3 results (REDEFINE 9); Zenagamtide (sc) -> Phase 3 initiation (CVOT); Zenagamtide (oral) -> Phase 3 initiation (AMAZE 9). Row group Blood & endocrine (orange #C94900 cell): Frehemgo/denecimig -> EU positive opinion, in a dark navy #00008F cell. Clinical milestone cells are light blue #C9E6FF with a check mark; the regulatory cell is navy #00008F with white text. Legend: light blue square #C9E6FF labelled Clinical milestones; navy square #00008F labelled Regulatory milestones. Right panel: pale blue #E4F3FF background. Three cards: (1) REIMAGINE 5 card, blue #0878CF label block with white text REIMAGINE 5 superscript 1 / CagriSema 1.0/1.0 mg / H2H vs. tirzepatide 5 mg, and two pale #E4F3FF boxes: 12.4% superior weight loss, 1.71% non-inferior HbA1c reduction; each box has a blue circular icon at its top-right corner (a scale icon on the left box and a pointing-hand icon on the right box). (2) REDEFINE 9 card, purple #8759E6 label block with white text REDEFINE 9 superscript 1 / CagriSema 1.0/1.0 mg, and one wide lavender #EEE9FF box with 21% weight loss at 68 weeks, with a purple scale icon at top-right. (3) Post-hoc analysis card, purple label block: Post-hoc analysis superscript 2 / (from REDEFINE 1) / CagriSema 2.4/2.4 mg, and two lavender boxes: 25% weight loss for women, and 27% weight loss for pre-menopausal women, each with a purple scale icon at top-right. Icons are simple white-outline line icons in circles. No charts or photographs.

Slide 12

12

Investor presentation

Q3 2026

novo

Pipeline progressing to fuel future growth with multiple key R&D

milestones going into 2027

Clinical milestones1

Regulatory milestones1

Project

Q4 2026

H1 2027

H2 2027

Diabetes

Ozempic® pill

US decision (25 mg)

CagriSema

Phase 3 results (REDEFINE 3)

UBT251 (tri-agonist)

Phase 2 results

Triple

Phase 2 results

Obesity

CagriSema

US decision

Phase 3 results (REDEFINE 11)

Cagrilintide

Phase 3 initiation (high-dose)

Phase 3 results (RENEW 1 & 2)

Amylin 355 (sc and oral)

Phase 2 results

UBT251 (tri-agonist)

Phase 1/2 results

Triple

Phase 1/2 results

Oral ACSL5i

Phase 1 results

Blood & endocrine disorders

Frehemgo® / denecimig

US decision

Etavopivat (SCD, Thalassemia)

US and EU submission (SCD)

US decision

Liver diseases

Oral semaglutide (MASH)

US decision

Efruxifermin

Phase 3 safety results (F1-F4)

Phase 3 results (F2-F3)

Cardiovascular diseases

Ziltivekimab (AMI)

Phase 3 results (ARTEMIS)

Consumer Rx

Exploring multiple indications

Clinical trial initiations

1Expected to be published in the given quarter or in the subsequent quarterly company announcement.

AMI: Acute myocardial infarction; EU: European Union; F: Fibrosis stage; MASH: Metabolic dysfunction-associated steatohepatitis; sc: subcutaneous; SCD: Sickle cell disease; US: United States

Note: Expected timing and qualification of R&D and regulatory milestones for inclusion in this table are based on current assessment, which is subject to change

Visuals: Table with columns: Category (merged colour blocks), Project, Q4 2026, H1 2027, H2 2027. Rows grouped by category: Diabetes (Ozempic pill; CagriSema; UBT251 (tri-agonist); Triple); Obesity (CagriSema; Cagrilintide; Amylin 355 (sc and oral); UBT251 (tri-agonist); Triple; Oral ACSL5i); Blood & endocrine disorders (Frehemgo / denecimig; Etavopivat (SCD, Thalassemia)); Liver diseases (Oral semaglutide (MASH); Efruxifermin); Cardiovascular diseases (Ziltivekimab (AMI)); Consumer Rx (Exploring multiple indications). Cell values: Ozempic pill Q4 2026 'US decision (25 mg)' on navy; Ozempic pill H1 2027 empty; Ozempic pill H2 2027 empty. CagriSema (Diabetes) H2 2027 'Phase 3 results (REDEFINE 3)' light blue. UBT251 (tri-agonist) H2 2027 'Phase 2 results' light blue. Triple (Diabetes) H2 2027 'Phase 2 results' light blue. CagriSema (Obesity) Q4 2026 'US decision' navy; H1 2027 'Phase 3 results (REDEFINE 11)' light blue. Cagrilintide Q4 2026 'Phase 3 initiation (high-dose)' light blue; H2 2027 'Phase 3 results (RENEW 1 & 2)' light blue. Amylin 355 H2 2027 'Phase 2 results' light blue. UBT251 (Obesity) H1 2027 'Phase 1/2 results' light blue. Triple (Obesity) H1 2027 'Phase 1/2 results' light blue. Oral ACSL5i H1 2027 'Phase 1 results' light blue. Frehemgo / denecimig H1 2027 'US decision' navy. Etavopivat Q4 2026 'US and EU submission (SCD)' navy; H2 2027 'US decision' navy. Oral semaglutide (MASH) H1 2027 'US decision' navy. Efruxifermin Q4 2026 'Phase 3 safety results (F1-F4)' light blue; H2 2027 'Phase 3 results (F2-F3)' light blue. Ziltivekimab (AMI) H1 2027 'Phase 3 results (ARTEMIS)' light blue. Consumer Rx row: H1 2027 to H2 2027 merged cell 'Clinical trial initiations' light blue. Legend: light blue square = Clinical milestones; navy square = Regulatory milestones. Navy cells are regulatory milestones; light blue cells are clinical milestones. No photographs, charts or logos other than the novo wordmark.

Slide 13

13

Investor presentation

Q3 2026

novo

Q3 2026 adjusted operating profit increased 27% to DKK 31.7 billion

Adj. operating profit favourably impacted by restructuring costs in 2025

Commercial investments towards Wegovy® and Ozempic® portfolio

R&D investments towards obesity and diabetes

Net profit of DKK 16.7 billion

Free cash flow of DKK 28.4 billion

in DKK million

Q3 2026 adjusted

Growth (CER)

9M 2026 adjusted

Growth (CER)

Sales 79,195 4% 227,746 2%

Gross profit 65,019 10% 182,872 2%

Gross margin 82.1% 80.3%

S&D costs (15,033) (9%) (42,107) (12%)

Percentage of sales 19.0% 18.5%

R&D costs (15.255) (1%) (36,998) 0%

Percentage of sales 19.3% 16.2%

Administrative costs (1,224) (34%) (3,673) (15%)

Percentage of sales 1.5% 1.6%

Other operating income and expenses (1,787) N/A (2,127) N/A

Operating profit 31,720 27% 97,967 8%

Operating margin 40.1% 43.0%

CER: Constant exchange rates; R&D: Research and development; S&D: Sales and distribution

Note: Adjusted P&L excludes certain exceptional and non-recurring effects, primarily of non-cash nature to enhance transparency and comparability of underlying operating performance.

Visuals: A financial table with a left-hand annotation panel. Table columns: row labels (in DKK million); Q3 2026 adjusted; Growth (CER); 9M 2026 adjusted; Growth (CER). Rows in order: Sales 79,195 | 4% | 227,746 | 2%. Gross profit 65,019 | 10% | 182,872 | 2%. Gross margin (italic) 82.1% | blank | 80.3% | blank. S&D costs (15,033) | (9%) | (42,107) | (12%). Percentage of sales (italic) 19.0% | blank | 18.5% | blank. R&D costs (15.255) | (1%) | (36,998) | 0%. Percentage of sales (italic) 19.3% | blank | 16.2% | blank. Administrative costs (1,224) | (34%) | (3,673) | (15%). Percentage of sales (italic) 1.5% | blank | 1.6% | blank. Other operating income and expenses (1,787) | N/A | (2,127) | N/A. Operating profit 31,720 | 27% | 97,967 | 8%. Operating margin (italic) 40.1% | blank | 43.0% | blank. No chart or photograph. The Growth (CER) columns are shaded light blue (#E4F3FF) from the header to the bottom row; the 9M 2026 adjusted column is unshaded. Dark navy horizontal rules separate the header from Sales, and Other operating income and expenses from Operating profit.

Slide 14

14

Investor presentation

Q3 2026

The 2026 outlook is raised, driven by increased expectations for

GLP-1 product sales

Expectations

4 November 2026

Guidance

Expectations

4 August 2026

-2% to +2% CER

in Danish kroner: in line with CER growth

Adj. sales growth1

-6% to 0% CER

in Danish kroner: ~1%-points lower

-2% to +2% CER

in Danish kroner: in line with CER growth

Adj. operating profit growth1

-6% to 0% CER

in Danish kroner: ~2%-points lower

Key modelling considerations

Financial items (net)

Loss of around DKK 1.6 billion

Loss of around DKK 1.1 billion

Effective tax rate

21% to 23%

21% to 23%

Capital Expenditure (CAPEX)

Around DKK 50 billion

Around DKK 55 billion

Free cash flow2

DKK 60 to 70 billion

DKK 45 to 55 billion

1Outlook is presented as adjusted sales growth and adjusted operating profit growth to exclude certain exceptional and non-recurring effects, primarily of non-cash nature to enhance transparency and comparability of underlying operating performance.

2Defined as net cash generated from operating activities less purchase of property, plant and equipment

CER: Constant exchange rates

Note: The financial outlook assumes of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 29 October 2026

Visuals: None photographic. Two blue chevron-tipped label bars (Adj. sales growth and Adj. operating profit growth) and light blue value panels form a guidance table with two data columns. Four grey chevron-tipped label bars (Financial items (net), Effective tax rate, Capital Expenditure (CAPEX), Free cash flow) sit beside light grey value panels. Table columns: Guidance label; Expectations 4 November 2026; Expectations 4 August 2026. Rows: Adj. sales growth, Adj. operating profit growth; then Financial items (net), Effective tax rate, Capital Expenditure (CAPEX), Free cash flow. Values as printed. A translucent white tint overlays the right-hand 4 August 2026 column, lightening it. The novo logo (emblem and wordmark) sits top right.

Slide 15

15

Investor presentation

Q3 2026

Preparing for the next wave of growth with Frehemgo® and

CagriSema launches planned in 2027

Frehemgo® aims to raise the bar in haemophilia care delivering

durable bleed protection with minimal treatment burden

Commercial readiness to secure a successful US launch of

CagriSema early next year

Durable bleed protection

demonstrated in FRONTIER

Once weekly, once every two

weeks or once monthly dosing

Ensuring speed to market from

approval to launch

Launch across all healthcare

channels

Seamless, safe and preferred

switching from SoC to Frehemgo®

Global roll-out

planned during 2027

Drive consumer efforts via

Novocare® and with partners

Raise awareness of CagriSema

ahead of launch

EU: European Union; SoC: Standard of care; US: United States

Note: Frehemgo® (denecimig) is approved in EU. Frehemgo® (denecimig) and CagriSema are pending regulatory approval in US.

Visuals: Eight icons and logos in two 2x2 grids. Left peach panel: (1) orange outline shield with a check mark, top-left cell, above 'Durable bleed protection demonstrated in FRONTIER'; (2) orange outline calendar with grid of cells and two binder rings at top, top-right cell, above 'Once weekly, once every two weeks or once monthly dosing'; (3) orange outline crossed shuffle arrows (one path crossing another, arrowheads on right), bottom-left cell, above 'Seamless, safe and preferred switching from SoC to Frehemgo®'; (4) Frehemgo Denecimig logo, bottom-right cell: the word FREHEMGO in bold blue #1E6FE0 letters with the final 'GO' fading to light teal, the ® mark at top right, and 'Denecimig' in smaller dark grey-navy regular type beneath it, above 'Global roll-out planned during 2027'. Right lavender panel: (5) purple outline circle with a check mark, top-left cell, above 'Ensuring speed to market from approval to launch'; (6) purple outline rocket angled up and right, top-right cell, above 'Launch across all healthcare channels'; (7) novocare logo, bottom-left cell: lowercase 'novocare' in bold navy #00008F with a small ® at the upper right, above 'Drive consumer efforts via Novocare® and with partners'; (8) purple outline icon of a monitor showing a small person-and-device grid with a speech bubble containing lines at its upper right, bottom-right cell, above 'Raise awareness of CagriSema ahead of launch'. Plus the novo wordmark logo top right: a navy #00008F stylised bull-head mark above lowercase 'novo' wordmark. All icons are flat line drawings with uniform stroke weight, no fill, no shadow; the icons are centred above their captions.

Slide 16

16 / Investor presentation / Q3 2026 / Investor contact information / Share information / Novo’s B shares are listed on the stock exchange in Copenhagen under / the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock / Exchange under the symbol ‘NVO’. / For more information, visit www.novonordisk.com / Investor relations contacts / Novo Nordisk A/S / Investor Relations / Novo Alle 1 / DK 2880 Bagsvaerd / Michael Novod / +45 3075 6050 [email protected] / Sina Meyer / +45 3079 6656 / [email protected] / Ida Schaap Melvold / +45 3077 5649 / [email protected] / Max Ung / +45 3077 6414 / [email protected] / Upcoming events / Christoffer Togo Solgaard-Tullin +45 3079 1471 / [email protected] / 3 February 2027 / Full-year 2026 financial results / Mads Berner Bruun / +45 3075 2936 / [email protected] / 18 March 2027 / Annual General meeting / Frederik Taylor Pitter (USA) / +1 609 613 0568 [email protected] / 5 May 2027 / Financial results Q1 2027 / Alex Bruce (USA) / +1 640 230 0276 [email protected] / 4 August 2027 / Financial results Q2 2027 / 3 November 2027 / Financial results Q3 2027

Slide 17

17 / Investor presentation / Q3 2026 / Appendix / Corporate strategy / Diabetes / Obesity / Cardiovascular & liver diseases / Blood & endocrine disorders / Regional information / Finance and Global Manufacturing & Supply

Visuals: Non-text visuals: one Novo logo in the bottom-right corner, consisting of the Novo stag emblem (a standing stag with a ring above its head) followed by the lowercase wordmark 'novo', both in solid #00008F. No photographs, charts, tables or diagrams.

Slide 18

18 / Investor presentation / Q3 2026 / novo

Novo has the potential to provide lasting health for millions more people

>550 million / People living with type 1 or type 2 diabetes

>900 million / People living with obesity

Driving change for lasting health

>13 million / People living with blood or endocrine disorders

>300 million / People living with liver diseases

>550 million / People living with cardiovascular diseases

Source: Diabetes atlas 11th edition. 2025; Ortner and Holzer. Milliman. 2025; Quek et al. The Lancet Gastroenterol Hepatol. 2023; World Obesity Atlas 2025 + 2026; Thomson et al. The Lancet Haematology. 2021; Yuanyuan et al. The Lancet. 2024; Cançado et al. Hematol Transfus Cell Ther. 2021; Caravaca-Fontán et al. 63rd European Renal Association Congress. 2026; Yan et al. Clin Epidemiol. 2020; Mameli et al. Endocrine. 2024; World Federation of Haemophilia Annual Global Survey. 2024; Willey et al. Nephrol Dial Transplant. 2023

Visuals: Diagram of five icon circles arranged in a vertical stack along the left edge of the stat rows, each joined by a thin navy curved connector line to the next, with navy dot endpoints at the top and bottom of the chain. Circles from top to bottom: blue #0878CF with a white outline icon of a pointing finger with a drop; purple #8759E6 with a white outline bathroom scale icon; orange-red #C94900 with a white outline drop-and-molecule icon; green #518300 with a white outline liver icon; crimson #DB315C with a white outline heart icon. Left of the stack is a large light-blue #ADDAFF ring with a white #FFFFFF inner disc containing the navy bold label 'Driving change for lasting health'. Figures are about 5.2% of slide height bold navy; descriptors about 2.2% regular with bold key phrase. Horizontal thin navy #00008F rules at about y 21.0, 40.2, 58.8 and 78.2 spanning from the text column to the right margin. Logo: novo emblem and wordmark in navy.

Slide 19

19

Investor presentation

Q3 2026

The updated corporate strategy aims to drive sustainable growth

Strengthen and expand our core

Build out future growth engines

Explore consumer Rx

Diabetes

Obesity

Blood & endocrine disorders

Science-led

Rx

Liver diseases

Consumer

- driven

Cardiovascular diseases

Unparalleled understanding

of metabolic diseases

Best-in-class biomolecular

engineering with oral peptide

delivery solutions

World-class manufacturing

at scale

Global footprint, and trusted local

healthcare relationships

Rx: Prescription

Visuals: Five coloured rectangles, a hatched circle with a central Rx loop icon, four navy circular icons with white line glyphs, three thin vertical separators, one navy horizontal rule, one small line icon per coloured bar, and a Novo Nordisk logo. Coloured bars (left column): Diabetes is a blue #0878CF bar with a white outline icon of a finger with a drop at its right end (about x 34.3-36.9%, y 37.7-41.4%); Obesity is a purple #8759E6 bar with a white outline icon of a bathroom scale at its right end (about x 34.4-36.8%, y 54.6-58.4%). Centre column: Blood & endocrine disorders is an orange #C94900 bar with a white outline icon of a drop above a molecule with nodes (about x 70.2-73.0%, y 37.0-41.7%); Liver diseases is a green #518300 bar with a white outline liver icon (about x 70.2-73.0%, y 51.0-54.5%); Cardiovascular diseases is a red #DB315C bar with a white outline anatomical heart icon (about x 70.6-72.5%, y 58.1-62.6%). Right column: a circle about 18.8% wide and 31.8% tall centred near x 85.9%, y 47.9%, filled with diagonal blue hatching on white, split into left and right halves by a vertical white gap at about x 85.6-86.3% with notched edges; at its centre sits a navy #00008F ring-shaped circular arrow with an arrowhead at the top, enclosing a solid navy disc with white 'Rx' text. Four circular navy #00008F icons, each 4.5% wide and 8.0% tall, top at y 69.5%: heart with pulse line (about x 12.8%); molecular node-and-link glyph (about x 35.6%); factory with sawtooth roof (about x 58.4%); person inside a circle holding a heart in a card with a return arrow (about x 81.1%); all glyphs are white outline. Three thin light grey vertical separators at x about 26.4%, 49.2% and 72.0%, spanning y 78.5-86.6%. The navy rule runs across the slide at y about 66.6%.

Slide 20

20 / Investor presentation / Q3 2026 / novo

Ambition to deliver 2026 to 2030 revenue CAGR in line with industry peers

Situation today / Strategy to deliver growth towards 2030

Semaglutide as foundational therapy, followed by ambitious / and competitive CagriSema launch planned early 2027

Grow and diversify our injectable franchise beyond semaglutide with / new launches every year including CagriSema in 2027, cagrilintide / in 2028, zenagamtide in 2029, and novel MoAs in 2030+

Wegovy® pill has expanded the oral GLP-1 market to / ~1.5 million patients within 8 months after launch

Expand oral leadership and scale capacity to be able to serve 10x / more people with obesity on oral GLP-1

Multiple late-stage assets in our future growth engines / (Frehemgo®, etavopivat, zaltenibart)

Grow our blood & endocrine business >50% by 2030 from 2026 base

Unique direct-to-consumer capabilities with increasing share / of business through telehealth channels

Enhance Novocare®, to further expand our business, improve / margins and explore consumer Rx indications

CAGR: compound annual growth rate; GLP-1: Glucagon-like peptide-1; MoA: Mechanism of action; Rx: Prescription / Note: Revenue growth in line with industry peers defined as 2026 to 2030 revenue CAGR / Source: IQVIA Xponent and internal estimates

Visuals: Four pairs of chevron panels, one pair per row. Left panels are light blue #92CDFF with navy #00008F text; right panels are solid navy #00008F with white text. Each left panel holds a white circle with a thin navy outline (about 5.2% of slide width by 9.3% of slide height) containing a navy line icon: row 1 a syringe (diagonal, plunger at top right, needle bottom left, graduation tick marks on barrel); row 2 a capsule pill split diagonally with a circle containing a minus sign at lower right; row 3 four diagonal arrows pointing outward from centre to the four corners (expand icon); row 4 a laptop outline with a mouse cursor arrow on its screen and a base line below. Top-right novo logo in navy: a stylised bull head mark followed by the lowercase wordmark novo. No photographs, charts or tables.

Slide 21

21 / Investor presentation / Q3 2026 / novo / Novo aims to navigate semaglutide loss of exclusivity by extending / today's business and building tomorrow's growth engines / Novo aims to grow into a larger and more diversified / company by 2035 / Diabetes / Obesity / Blood & endocrine disorders / Liver diseases / Cardiovascular diseases / Consumer Rx / 2026 / 2035 / ILLUSTRATIVE / Strategy focuses on extending current franchise while launching / next wave of innovation / Fiercely compete for sema volumes in both pre- and post-LoE markets / Launch next wave of diabetes & obesity innovation, with potential multi-blockbuster launches every year through 2030 / Expand oral leadership through new oral formulations and new patents / Business development / Build future growth engines by launching next wave of innovation within blood & endocrine, liver and cardiovascular / Explore consumer Rx by leveraging scientific and commercial synergies / LoE: Loss of Exclusivity; Rx: Prescription

Visuals: Left panel: two donut charts with a legend above. Chart 1, titled 2026, shows about 70% Diabetes (#0878CF blue), about 22% Obesity (#8A5BE3 purple), and about 8% Blood & endocrine disorders (#C94900 orange) with no other segments; the hole is filled #E6DFD7 with the label 2026 in bold navy. Chart 2, titled 2035, shows about 28% Diabetes (blue, top right), about 40% Obesity (purple, lower right and bottom), about 10% Cardiovascular diseases (pink #DB3A63, lower left), about 12% Liver diseases (green #528200, left), about 10% Blood & endocrine disorders (orange, upper left) and about 5% Consumer Rx (navy hatched pattern, top); segment boundaries are softly blended. Values are estimates, not printed. The hole is filled #E6DFD7 with label 2035 in bold navy. Legend: blue square Diabetes, purple square Obesity, orange square Blood & endocrine disorders, green square Liver diseases, pink square Cardiovascular diseases, navy hatched square Consumer Rx. The word ILLUSTRATIVE is underlined in regular navy caps below the charts. Right panel: a vertical stripe bar about 3% wide at the left of the bullets, blending blue #0878CF at top into purple #8A5BE3 at bottom; below it a stack of three squares orange #C94900, green #528200, pink #DB3A63; below that a navy hatched square for Consumer Rx. Three separators are thin navy horizontal rules. A navy arrow shape (#00008F) with a pointed top stands at the right edge, containing the white text Business development.

Slide 22

22 / Investor presentation / Q3 2026

External innovation is a key enabler to expand the pipeline and strengthen competencies in AI

Strengthen and expand our core through new assets, technology and capacity

Build out future growth engines through early and late-stage pipeline assets

Explore new partnerships across consumer and AI

Adding consumer partnerships

ro / hims / COSTCO WHOLESALE

Partnering with leading AI providers

Copilot / OpenAI / ANTHROPIC / aws

Note: Non exhaustive

Visuals: Logo grid, no chart or photograph. Left column (Strengthen and expand our core): a vertical bar in a blue-to-violet diagonal gradient (blue #0A78D2 at top-left fading to violet #8A5CE6 at bottom-right) beside three navy-outlined boxes containing the logos Septerna (blue wordmark), United Laboratories (red square mark with Chinese characters 聯邦制藥 and 'UNITED LABORATORIES' in black caps), and Emisphere (navy serif-style wordmark 'Emisphere' with a light-blue arrow underline). Middle column (Build out future growth engines): a vertical bar in a vertical gradient from burnt orange #C84B00 at top through green #4F8A00 in the middle to crimson #DB3058 at bottom, beside five navy-outlined boxes containing Forma Therapeutics (navy and lime-green chevron mark with 'forma' and 'THERAPEUTICS.'), OMEROS (orange swirl mark with teal 'OMEROS' caps and registered mark), akero (black lowercase wordmark with blue arrow in the e-slot), Cardior (sage-green ribbon mark with green 'Cardior'), and prothena (teal stylised p mark with teal 'prothena' and registered mark). Right column on #EEEAE4 panel: black 'ro' wordmark, black serif 'hims' wordmark, red-and-blue 'COSTCO WHOLESALE' logo; then Microsoft Copilot multicolour swirl icon, black 'OpenAI' wordmark with knot mark, black 'ANTHROPIC' caps wordmark, and dark grey 'aws' wordmark with orange smile arrow. No photographs; all logos are flat and unboxed in the right panel.

Slide 23

23

Investor presentation

Q3 2026

We measure our performance against our 2030 ambitions

Grow and diversify

pipeline

Drive sustainable

growth

Deliver attractive

returns

• Launch >5 multi-blockbusters by 2030 and

deliver >150 bDKK pipeline sales in 2035

• ≥5 Phase 3 programmes in obesity and

diabetes1

• ≥5 Phase 3 programmes in other TAs1

• Deliver 2026-30 revenue CAGR in line with

industry peers

• Scale capacity to be able to serve 10x

more people with obesity on oral GLP-1

• Serve >60m patients globally by 2030

• Maintain a broadly stable operating

margin

• Maintain an attractive dividend per share

1Enter or complete, including new and current programmes

CAGR: Compound annual growth rate; GLP-1: Glucagon-like peptide-1; TAs: Therapy areas;

Note: All ambitions by 2030 from a 2026 baseline; revenue and margin assumptions are all based on adjusted metrics; Industry peers: Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co, Biogen, Pfizer, Bristol Myers Squibb

Visuals: Three circular icons in a row, each a solid navy circle about 9.8% of slide width in diameter with a white line-art pictogram inside. Icon 1 (left, grow and diversify pipeline): a stacked arrangement of three white outlined chevron arrows across the top, with outlined square blocks below in a staggered grid, and three blocks filled with white diagonal hatching and one dotted-fill block. Icon 2 (centre, drive sustainable growth): four white outlined vertical bars of rising height on a baseline, with a white line arrow rising diagonally up to the right across them and an arrowhead at the top right. Icon 3 (right, deliver attractive returns): a white outlined coin with a white dollar sign and small motion ticks at its upper left, above an open white outlined hand holding it palm up. No charts with axes or data values, no photographs, no tables.

Slide 24

Novo is applying an updated modality approach to address patient

needs

24

Investor presentation

Q3 2026

Prioritising modalities to build upon current leadership while making strategic

investments in emerging areas

Strategy

Modality

Diabetes

Obesity

Blood &

endocrine

disorders

Liver

diseases

Cardio-

vascular

diseases

Grow

Proteins &

peptides

Build

Oligo-

nucleotides

Small

molecules

Partner

Antibodies

Gene

therapy

Injectable in pipeline

Oral in pipeline

Preclinical/research

Solving for patient needs across multiple

parameters

Efficacy

Safety

Comorbidities

Disease modification

Experience optimisation

Convenience

Tolerability

Affordability

Visuals: A matrix table with 7 columns (Strategy, Modality, Diabetes, Obesity, Blood & endocrine disorders, Liver diseases, Cardio-vascular diseases) and 5 body rows grouped into three strategy bands: Grow (Proteins & peptides), Build (Oligonucleotides, Small molecules), Partner (Antibodies, Gene therapy). Each indication cell holds pictograms: a syringe icon = Injectable in pipeline, a pill icon = Oral in pipeline, a check-mark icon = Preclinical/research. Row contents: Proteins & peptides: Diabetes injectable and oral; Obesity injectable and oral; Blood & endocrine injectable and oral; Liver injectable and oral; Cardio-vascular injectable and oral. Oligonucleotides: Diabetes injectable; Obesity injectable; Blood & endocrine injectable; Liver injectable; Cardio-vascular injectable. Small molecules: Diabetes check; Obesity oral; Blood & endocrine oral; Liver check; Cardio-vascular oral. Antibodies: Diabetes empty; Obesity empty; Blood & endocrine injectable; Liver empty; Cardio-vascular injectable. Gene therapy: Diabetes check; Obesity check; Blood & endocrine check; Liver empty; Cardio-vascular empty. Each modality cell has a small line icon at its right: peptide ribbon, pipette-like oligonucleotide, molecular ball-and-stick, antibody Y shape, DNA helix. Legend below the table: three circled pictograms with labels. Right panel: a navy circle at centre with a white person-with-plus outline, surrounded by six circular line icons (shield with check for Safety, scale with syringe for Efficacy, heart-with-pulse and hand for Comorbidities, hand with plus for Convenience, check-circle for Tolerability, coins and banknote for Affordability) and two curved labels on a ring around the circle. Pictograms are navy outlines on white circles; no photographs.

Slides 25 to 98 continue in the full text file.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview